Welcome to Launch Code, an executive briefing designed to surface the hidden risks that derail healthcare launches. Each edition isolates one risk and equips leaders with decision infrastructure to reduce exposure, accelerate adoption, and protect valuation before reversing course becomes costly.
Most growth forecasts are built on one assumption:
performance will improve over time.
Win rates increase.
Sales cycles shorten.
Expansion becomes easier.
It rarely happens.
Not because the product is weak.
But because the conditions required for growth to accelerate were never in place.
Growth doesn’t improve because time passes.
It improves when resistance declines.
And resistance declines only when specific market conditions are present.
In this briefing:
- Forecast risk comes with warnings
- Dealing with risk later is expensive
- Detect your forecast risk
- Science won’t win the market
- Protect your launch
The question isn’t whether your product is better.
It’s whether the market is primed for change.
Five conditions determine whether resistance will decline. If even two are weak, your forecast is at risk—regardless of product strength.
These are not post-launch outcomes.
They are pre-launch design decisions.
If you’re 12 – 24 months from launch, you won’t feel resistance yet.
That’s the trap.
Early markets are too quiet to reveal the friction that will later stall growth.
The wrong question is: “Are we seeing friction yet?”
The right question is: “Are we building the conditions that will make friction decline?”
Too many teams wait for resistance to become visible before taking it seriously. By the time resistance is visible:
Everyone is reacting.
No one is fixing the real problem.
The Commercial Growth Scorecard is built to help leadership teams assess whether these five conditions are strong enough to reduce forecast risk.
It’s not a messaging exercise. It’s not marketing theater. It’s forecast risk detection. Because once forecast risk becomes visible in the numbers, correction is already expensive.
Weak signals suggest elevated risk.
Mixed signals suggest instability.
Strong signals suggest the market may be ready to change.
Wall Street modeled a billion-dollar drug. Provenge peaked at $325 million just three years after launch. The next year, Dendreon—the company behind the blockbuster—filed for bankruptcy.
On paper, Provenge looked like a breakthrough.
It was the first FDA-approved autologous cellular immunotherapy for metastatic prostate cancer, backed by survival data and enormous expectations.
But the launch ran into the market.
Provenge improved survival by 4.1 months—but produced no tumor shrinkage or PSA decline, the signals oncologists were trained to associate with treatment success.
At the same time, it introduced a complex workflow: leukapheresis, cell processing, manufacturing coordination, reinfusion scheduling, reimbursement friction, and infusion burden.
The science was novel.
The behavior change was massive.
And the market never believed the benefit justified the disruption.
Provenge crossed the FDA threshold.
It never crossed the Market Belief Threshold.
Then came Zytiga and Xtandi—therapies that delivered survival benefits through dramatically simpler workflows.
No apheresis.
No infusion coordination.
No operational redesign.
Provenge asked oncologists to change how they practiced. The alternatives didn’t.
That’s why the growth curve never inflected for Dendreon.
Approval enables availability. Belief drives adoption.
If your growth model assumes improving performance over time, pressure-test it now.
Because growth doesn’t fail gradually.
It fails when the conditions required for acceleration were never there to begin with.
Pressure-test whether your market is positioned to cross the belief threshold before capital is scaled.
A one-page executive summary of the five conditions that determine whether growth accelerates—or fails.
Get the Boardroom Brief
